Search

Subject Selinexor -- AML -- relapsed -- refractory

1. A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Issue 13 (10th November 2021)

Authors:
Sweet, Kendra; Bhatnagar, Bhavana; Döhner, Hartmut; Donnellan, Will; Frankfurt, Olga; Heuser, Michael; Kota, Vamsi; Liu, Hongtao; Raffoux, Emmanuel; Roboz, Gail J.; Röllig, Christoph; Showel, Margaret M.; Strickland, Stephen A.; Vives, Susana; Tang, Shijie; Unger, Thaddeus J.; Joshi, Anita; Shen,...
Journal:
Leukemia & lymphoma
Issue:
Volume 62:Issue 13(2021)
Page Start:
3192
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search

  • Selinexor -- AML -- relapsed -- refractory 1